NCT00150462 - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Waldenstrom's MacroglobulinemiaNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma

Interventions

DRUG

Carfilzomib

Administered as an IV bolus dose

DRUG

Dexamethasone

Administered orally prior to carfilzomib

Trial Locations (5)

Memorial Sloan Kettering Cancer Center, New York

Weil Medical College of Cornell University, New York

Herbert Irving Comprehensive Cancer Center, Columbia University, New York

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Tower Cancer Research Foundation, Beverly Hills